MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today the initiation of a clinical trial of its telomerase cancer vaccine, GRNVAC1, in patients with acute myelogenous leukemia (AML) in complete remission. The vaccine is produced from a patient’s blood using a unique process that generates highly activated dendritic cells (DC) that contain RNA coding for the protein component of telomerase. This new approach to cancer immunotherapy has been clinically shown to safely generate high levels of cytotoxic lymphocytes that kill telomerase positive cancer cells after as few as six weekly injections into the skin.
